HG-004

N/A

Report date: 2023/10/26 16:50:48

Base Information

Drug NameHG-004
Drug Alias NameHG-004
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV2 vector
Mechanisms of ActionGene modulatorsRPE65 gene transference
TargetsRetinoid isomerohydrolase
Therapy Area/IndicationsRetinal DiseasesLeber Congenital Amaurosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesHuiGene Therapeutics Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesHuidaGene Therapeutics Co Ltd
Inactive CompaniesHuiGene Therapeutics Ltd
Active IndicationsRetinal DiseasesLeber Congenital Amaurosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A